HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.

AuthorsAtsushi Ogata, Masayasu Kitano, Naoaki Hashimoto, Tsuyoshi Iwasaki, Teruaki Hamano, Eizo Kakishita
JournalJournal of bone and mineral metabolism (J Bone Miner Metab) Vol. 20 Issue 4 Pg. 240-2 ( 2002) ISSN: 0914-8779 [Print] Japan
PMID12115071 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Osteocalcin
  • Alendronate
Topics
  • Adult
  • Alendronate (therapeutic use)
  • Biomarkers (blood)
  • Bone Diseases (blood, complications, drug therapy, physiopathology)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Multiple Myeloma (blood, complications, drug therapy, physiopathology)
  • Osteocalcin (blood)
  • Osteolysis (drug therapy)
  • Pain (blood, drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: